Clinical Trials
Receiving Tomorrow's Treatments Today at Bethesda
When you're looking for the most advanced drug treatments available, turn to the clinical research experts at Bethesda Memorial Hospital's Research Center.
These clinical trials are listed for informational purposes, and are not to be used outside of a clinical trial setting. Please contact Bethesda Research Center at (561) 374-5020 for full particulars regarding enrollment of any clinical trial.
Active Clinical Trials
(Updated March 2012)
1st Line Lung Cancer
BRISTOL-MYERS SQUIBB CA184104
Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin versus Placebo in Addition to Paclitaxel and Carboplatin in Subjects with Stage IV/Recurrent Non-Small Cell Lung.
AstraZeneca Protocol D7913N00017
An Open Label, Multi-center, IRESSA™ Clinical Access Program of Gefitinib 250 mg (IRESSA™) for the continued treatment of patients in the United States who are currently benefiting or have benefited from gefitinib treatment
Ovarian
Sanofi Aventis EFC 10260
A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled, Randomized Study of Ombrabulin in Patients with Platinum-Sensitive Recurrent Ovarian Cancer Treated with Carboplatin/Paclitaxel
Chronic Myeloid Leukemia
Bristol Myers Squibb CA180330
Studying Interventions for Managing Patients with Chronic Myeloid Leukemia in the Chronic Phase: The 5-Year Prospective Cohort Study (SIMPLICITY)
Breast
ACOSOG (Z1072)
A Phase II Trial Exploring the Success of Cryoablation Therapy in the Treatment of Invasive Breast Carcinoma
Just In Time Studies
PIX306
A Randomized, Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed after Therapy with CHOP-R or an Equivalent Regimen and are Ineligible for Stem Cell Transplant
CD-ON-MEDI-573-1030
A Phase 1b/2 Randomized Studey of MEDI-573 in Combination with an Aromatase Inhibitor (AI) Versus AI Alone in Women with Metastatic Breast Cancer (MBC).
CD-ON-MEDI-573-1028
A Phase 1b/s, Open-label, Randomized Study of MEDI-573 in Combination with Sorafenib Versus Sorafenib Alone in Adult Subjects with Unresectable or Metastatic Hepatocellular Carcinoma.
NLG-0405
A Phase III Study of Chemotherapy and Chemoradiotherapy With or Without HyperAcute(r)-Pancreas (algenpantucel-L) immunotherapy in Subjects with Surgically Resected Pancreatic Cancer.
PCYC-1001
Phase II Study of Coagulation Factor Vlla Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment with Gemcitabine
AZD0102C00004:
A Phase II, Randomized, Double-Blind Study of Anastrozole +/- AZD8931 in Postmenopausal Women with Hormone Receptor Positive, Endocrine Therapy Naïve, Locally Advanced or Metastatic Breast Cancer (MINT study)
PX-866-003:
The study of PX-866 and Cetuximab in Patients with Incurable Metastatic Colorectal Cancer and/or in Patients with Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
PX-866-002:
Phase I/II Study of PX-866 and Docetaxel in Patients with Solid Tumors Metastatic NSCLC or Metastatic SCCHN
U31287-A-U201: Advanced NSCLC
Randomized, Placebo-controlled, Double-blind Phase 1b/2 Study of U3-2187 (AMG 888) in Combination with Erlotinib in EGFR Treatment Naive Subjects with Advances Non-Small Cell Lung Cancer(NSCLC) who have progressed on at least one prior chemotherapy.
Cardiac
Boston Scientific
Longitudinal Surveillance Registry of the ACUITY Spiral Lead
Abbott-CANOPY-Protocol 10-720
Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy
Chronic Limb Ischemia
ABBOTT - Absolute Pro® Momentum™ Trial; PROTOCOL #10-110
A Prospective, Multicenter, Non-Randomized, Single-Arm Clinical Trial to Evaluate the Safety and Effectiveness of the Absolute Pro® Peripheral Self-Expanding Stent System and the Absolute Pro® LL Peripheral Self-Expanding Stent System in the Treatment of Subjects with Atherosclerotic De Novo or Restenotic Lesions in the Native Superficial Femoral Artery and/or Native Proximal Popliteal Artery
AASTROM-Protocol 55-1009-01 REVIVE
A Multicenter, Randomized, Double-blind, Placebo-controlled Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Ixmyelocel-T in Subjects with Critical Limb Ischemia and No Options for Revascularization
Contact Us
The Bethesda Research Center is located in the Bethesda Professional Plaza, next to Bethesda Memorial Hospital. For full particulars regarding enrollment of any clinical trial, call (561) 374-5020.